Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 3, Issue 3, 2009, Pages 162-167

  Leung, Yvette ^a   Sparrow, Miles P ^b   Schwartz, Marc ^a   Hanauer, Stephen B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b ALFRED HOSPITAL   (Australia)

Author keywords

6 mercaptopurine; Allopurinol; Azathioprine; Inflammatory bowel disease; Metabolites

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; LIVER ENZYME; MERCAPTOPURINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; ULCERATIVE COLITIS;

EID: 67651083623     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.02.003     Document Type: Article

References (37)

1. Akobeng A.K. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment Pharmacol Ther 27 (2008) 11-18
2. Candy S., Wright J., Gerber M., Adams G., Gerig M., and Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37 (1995) 674-678
3. Markowitz J., Grancher K., Kohn N., Lesser M., and Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119 (2000) 895-902
4. Pearson D.C., May G.R., Fick G., and Sutherland L.R. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2 (2000) CD000067 Review
5. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
6. Lemann M., Mary J.Y., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006) 1054-1061
7. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., and Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55 (2006) 47-53
8. Timmer A., McDonald J.W., and Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 1 (2007 Jan 24) CD000478 Review
9. Karran P., and Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 8 (2008) 24-36
10. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43 (1992) 329-339
11. Tiede I., Fritz G., Strand S., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111 (2003) 1133-1145
12. Thomas C.W., Myhre G.M., Tschumper R., et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 312 (2005) 537-545
13. Dubinsky M.C., Yang H., Hassard P.V., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122 (2002) 904-915
14. Ansari A., Arenas M., Greenfield S.M., et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 28 (2008) 973-983
15. Sparrow M.P., Hande S.A., Friedman S., et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 22 (2005) 441-446
16. Sparrow M.P., Hande S.A., Friedman S., Cao D., and Hanauer S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 5 (2007) 209-214
17. Witte T.N., and Ginsberg A.L. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol 22 (2008) 181-185
18. Ansari A., Elliott T., Baburajan B., et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 28 (2008) 734-741
19. Rahhal R.M., and Bishop W.P. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 12 (2008) 1678-1682
20. Holtmann M., Schreiner O., Kohler H., et al. Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine. Dig Dis Sci 48 (2003) 1503-1505
21. Vernier-Massouille G., Cosnes J., Lemann M., et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 56 (2007) 1404-1409
22. Lennard L., and Singleton H.J. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 583 (1992) 83-90
23. Lennard L., and Singleton H.J. High-performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B Biomed Appl 661 (1994) 25-33
24. Harvey R.F., and Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1 (1980) 514
25. Schroeder K.W., Tremaine W.J., and Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 (1987) 1625-1629
26. Cuffari C., Theoret Y., Latour S., and Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 39 (1996) 401-406
27. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
28. Roblin X., Serre-Debeauvais F., Phelip J.M., et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 21 (2005) 829-839
29. Osterman M.T., Kundu R., Lichtenstein G.R., and Lewis J.D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130 (2006) 1047-1053
30. Zimm S., Collins J.M., O'Neill D., Chabner B.A., and Poplack D.G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34 (1983) 810-817
31. Chocair P., Duley J., Simmonds H.A., et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 342 (1993) 83-84
32. Wong D.R., Derijks L.J., den Dulk M.O., Gemmeke E.H., and Hooymans P.M. The role of xanthine oxidase in thiopurine metabolism: a case report. Ther Drug Monit 29 (2007) 845-848
33. Ansari A., Aslam Z., De Sica A., et al. The influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment Pharmacol Ther 28 6 (2008) 749-757
34. Duley J.A., Chocair P.R., and Florin T.H. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment Pharmacol Ther 22 (2005) 1161-1162
35. Salim A.S. Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. J Lab Clin Med 119 (1992) 710-717
36. Jarnerot G., Strom M., Danielsson A., et al. Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. Aliment Pharmacol Ther 14 (2000) 1159-1162
37. Joelsson M., Andersson M., Bark T., et al. Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis. A randomized placebo-controlled double-blind study. Scand J Gastroenterol 36 (2001) 1179-1184